Combined treatment with dipeptidyl peptidase‐4 inhibitor (sitagliptin) and angiotensin‐II type 1 receptor blocker (losartan) suppresses progression in a non‐diabetic rat model of steatohepatitis
Sign Up to like & getrecommendations! Published in 2017 at "Hepatology Research"
DOI: 10.1111/hepr.12860
Abstract: Dipeptidyl peptidase‐4 (DPP4) inhibitors (DPP4‐I) are oral glucose‐lowering drugs for type 2 diabetes mellitus. Previously, we reported that DPP4‐I (sitagliptin) exerted suppressive effects on experimental liver fibrosis in rats. Blockade of the renin–angiotensin system by… read more here.
Keywords: type receptor; receptor blocker; dipeptidyl peptidase; type ... See more keywords